Celgene International Ii Sarl

Mark Mills

Esther Martinborough

Marcus F Boehm

Premji Meghani

Liming Huang

Adam Richard Yeager

Manisha Moorjani

Junko Tamiya

Andrew Richard Novak

Enugurthi Brahmachary

Thomas Fowler

Michael Knaggs

Daniel Glynn

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where '' represents either or both the R and S form of the compound): where A, B, C, Y, Y, Z, R, R, R, R, R, W, n, p and q are as defined herein.

GLP-1 receptor modulators

Growing community of inventors

Carlton, United Kingdom

Mark Mills